PRVB: Q3 2022 Update & Outlook
Full rundown on Provention Bio (PRVB) as the Q3 2022 quarterly call and November 17 PDUFA dates approach…
PRVB: Three Key Takeaways From The FDA Delay
Here are three key takeaways from the FDA’s response to Provention Bio (PRVB)’s BLA application for teplizumab…
PRVB: What To Expect This Week
Here’s what to expect this week from Provention Bio (PRVB) as the FDA’s original PDUFA date hits on Friday…
PRVB: Hold Nose, Buy More
Provention Bio (PRVB) announced the FDA needs more PK/PD data. Here’s why I’m buying more on this pullback…
Provention Drops The F Bomb… Again
Provention Bio (PRVB) announced an offering after the bell yesterday, on a day teh stock hit a 52-week high. Here’s what I plan to do…
[Trade Alert] Happily Wrong
Provention Bio (PRVB) successfully priced a $100 million offering. Here are all the details, along with three key data takeaways from the ADA meeting…